Tislelizumab as monotherapy or in sequential combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma: A prospective, phase II clinical study. NEO-ERA-01: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results